-

$undefined

N/A

(N/A)

Novartis NYSE:NVS Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Location: Lichtstrasse 35, Basel, 4056, Switzerland | Website: https://www.novartis.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

238.9B

Cash

7.137B

Avg Qtr Burn

N/A

Short % of Float

0.25%

Insider Ownership

0.00%

Institutional Own.

7.16%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vanrafia® (atrasentan) Details
Proteinuria reduction in primary IgA nephropathy (IgAN)

Approved

Update

Fabhalta® (iptacopan) Details
IgA nephropathy, Kidney disease

Approved

Quarterly sales

Approved

Quarterly sales

SCEMBLIX Details
Chronic myelomonocytic leukemia, Blood cancer, Cancer, Leukemia

Approved

Quarterly sales

Fabhalta® (iptacopan) Details
Kidney disease, C3 Glomerulopathy

PDUFA

Adcomm

Remibrutinib [BTK inhibitor] Details
Chronic spontaneous urticaria

NDA

Submission

Phase 3

Data readout

Fabhalta® (iptacopan) Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Data readout

Leqvio (inclisiran) Details
Atherosclerotic cardiovascular disease

Phase 3

Update

Tafasitamab (CD19) Details
Cancer, B-cell malignancies, Marginal zone lymphoma, Follicular lymphoma

Phase 3

Update

Lutathera® Details
Gastroenteropancreatic neuroendocrine tumors, Cancer

Phase 3

Update

Intrathecal onasemnogene abeparvovec (OAV101 IT) Details
Kidney disease, Glomerular diseases, IgA nephropathy

Phase 3

Update

Phase 2/3

Update

Atrasentan Details
Glomerular diseases, Kidney disease

Phase 2

Data readout

CHK-336 Details
Primary hyperoxaluria

Phase 1

Update